FDA approved the vaccine against Covid-19 Novavax

FDA has approved the use of the Novavax Crown Vaccine

Ssilver/depositphotos

The US Food and Drug Supervision Office (FDA) has approved the Novavax Covid-19 vaccine.

It is intended for people over 65 years of age and children from 12 years who have at least one The underlying diseasewhich increases the risk of severe disease.

About it writes CNN.

« Market research and statistics of the US Center for Control and Prevention of US Diseases indicate that the elderly and persons with comorbidities are population groups that are most commonly contacted by seasonal vaccination against COVID-19.

This important milestone demonstrates our affection for them and is a significant step on the way to the availability of our protein vaccine « , – said the President and Chief Executive Director of Novavax John Jacobs.

The Novavax vaccine against Covid-19 is developed by more traditional protein technology, unlike the Pfizer/Biontech and Moderna vaccine.

Novavax was ready for full approval on April 1, but FDA has postponed the decision searching for additional data. The company requires post -marketing studies aimed at studying the risk of myocarditis and pericarditis (inflammation of the heart muscle and membrane surrounding the heart) in people who receive a vaccine.

According to the US Centers and Prevention Centers (CDC), Novavax has recorded several such cases during the tests of the vaccine, but these states were rarely reported.

CDC advisers to vaccines consider changes to the recommendations on who should be made annually vaccination against coronavirus. At the meeting last month, the committee discussed a recommendation focused on the elderly, people with weakened immunity and, probably, at those who have an increased risk of infection.

Earlier we toldthat scientists have created a vaccine that will potentially protect against types of coronaviruses that are still unknown.